GlassScriptPhysician profile
Renee Rennick
NPI 1760530521
$3,929.31
in general payments reported to CMS, 2019-2025
18 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $734 · 2023: $1,236 · 2024: $1,405 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,916.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,627.93 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $581.15 | 2021-2024 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $394.19 | 2021-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $237.33 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $209.17 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $180.85 | 2022-2024 | Dupixent |
| Celgene Corporation | $170.73 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $121.25 | 2023-2024 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.51 | 2023-2024 | Xifaxan |
| Ardelyx, INC. | $70.78 | 2023-2024 | Ibsrela |
| Genzyme Corporation | $50.19 | 2022-2024 | |
| Pfizer INC. | $49.94 | 2024 | |
| Braintree Laboratories, INC. | $37.04 | 2022-2023 | Sutab, Suflave |
| Gilead Sciences, INC. | $18.92 | 2021 | |
| Stryker Corporation | $17.72 | 2025 | Neptune, Pedi-Pom |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $16.14 | 2023 | |
| Aimmune Therapeutics, INC. | $14.49 | 2024 | |
| Madrigal Pharmaceuticals | $13.98 | 2024 | Resmetirom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Rennick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.